- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03419533
Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers (B Part Of It)
An Observational Cross-sectional Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This carriage study of a cohort of school leavers in South Australia (SA) will provide an opportunity to assess carriage rates in the young adult population (school leavers) following introduction of a 4CMenB vaccination program in senior school students from 2017-2018.This will allow a comparison of carriage prevalence in the two years (2018 and 2019) following implementation of the school program to assess impact on carriage at a population level and compare carriage prevalence in vaccinated versus non-vaccinated groups. Assessment of any association between risk factors and prevalence of nasopharyngeal carriage in school leavers will be made and compared between vaccinated and unvaccinated students.
School leavers are defined as students who were enrolled in year 12 at school in the preceding year of recruitment and have been chosen as they are likely to have the highest carriage rates. A high proportion (approximately two thirds) of students will be immunised by the time of throat swab collection in years 2018 and 2019. Assessing carriage in both vaccinated and unvaccinated cohorts will further inform the effect of 4CMenB vaccine on carriage at a population level. This will help determine any herd immunity impact of 4CMenB vaccine and persistence of any effect.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
South Australia
-
Adelaide, South Australia, Australien, 5006
- Women's and Children's Hosptial
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- South Australian school leavers between 17 to 25 years of age (enrolled in year 12 in the previous year ie year 2018, students are eligible if they were enrolled in year 12 in 2017, year 2019, students are eligible if they were enrolled in year 12 in 2018).
Exclusion Criteria:
- No exclusion criteria
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
2018 school leavers
South Australian school leavers in 2018 (year 12 in 2017)
|
|
2019 school leavers
South Australian school leavers in 2019 (year 12 in 2018)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Estimate the Difference in Carriage Prevalence of Disease Associated Genogroups of N. Meningitidis (A, B, C, W, X, Y) Between School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018), Following a 4CMenB School Immunisation Program
Zeitfenster: 2018 to 2019
|
As measured by PCR in school leavers in 2018 and 2019
|
2018 to 2019
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Estimate the Difference in Carriage Prevalence of All N. Meningitidis Genogroups Between South Australian School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018)
Zeitfenster: 2018 to 2019
|
As measured by PCR in school leavers in 2018 and 2019
|
2018 to 2019
|
|
Estimate the Difference in Carriage Prevalence of Each N. Meningitidis Genogroup (A, B, C, W, X, Y) Between South Australian School Leavers in 2018 (Year 12 in 2017) and 2019 (Year 12 in 2018)
Zeitfenster: 2018 to 2019
|
As measured by PCR in school leavers in 2018 and 2019
|
2018 to 2019
|
|
Across Years, Estimate the Difference in Carriage Prevalence of N. Meningitidis Genogroups Causing Disease (A, B, C, W, X, Y) Between South Australian School Leavers Who Received 4CMenB Vaccine and Unvaccinated Students
Zeitfenster: 2018 to 2019
|
As measured by PCR in vaccinated and unvaccinated school leavers
|
2018 to 2019
|
|
Across Years, Estimate the Difference in Carriage Prevalence of All N. Meningitidis Genogroups Between South Australian School Leavers Who Have Received 4CMenB and Unvaccinated Students.
Zeitfenster: 2018 to 2019
|
As measured by PCR in vaccinated and unvaccinated school leavers in 2018 and 2019
|
2018 to 2019
|
|
Across Years, Estimate the Difference in Each N. Meningitidis Genogroup (A, B, C, W, X, Y) Carriage Prevalence Between South Australian School Leavers Who Received 4CMenB Vaccine and Unvaccinated Students
Zeitfenster: 2018 to 2019
|
As measured by PCR in vaccinated and unvaccinated school leavers
|
2018 to 2019
|
|
Identify Characteristics Associated With Carriage Prevalence of All N. Meningitidis Genogroups in South Australian School Leavers in 2018/2019
Zeitfenster: 2018 to 2019
|
As measured by PCR in school leavers
|
2018 to 2019
|
|
Identify Characteristics Associated With Carriage Prevalence of N. Meningitidis Genogroups Causing Disease (A, B, C, W, X, Y) in South Australian School Leavers in 2018 /2019
Zeitfenster: 2018 to 2019
|
As measured by PCR in school leavers
|
2018 to 2019
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Describe Carriage Density of N. Meningitidis Genogroups as Measured by qPCR in School Leavers
Zeitfenster: 2018 to 2019
|
Density of N. meningitides by qPCR
|
2018 to 2019
|
|
Describe Genome Sequencing of Pathogenic N. Meningitidis (A, B, C, W, X, Y) in Carriage Among School Leavers.
Zeitfenster: 2018 to 2019
|
Whole genome sequencing of N. meningitidis
|
2018 to 2019
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Marshall HS, McMillan M, Koehler A, Lawrence A, MacLennan J, Maiden M, Ramsay M, Ladhani SN, Trotter C, Borrow R, Finn A, Sullivan T, Richmond P, Kahler C, Whelan J, Vadivelu K. B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis. BMJ Open. 2019 May 6;9(5):e027233. doi: 10.1136/bmjopen-2018-027233.
- McMillan M, Bednarz J, Leong LEX, Lawrence A, Marshall HS. Impact of COVID-19 Containment Strategies and Meningococcal Conjugate ACWY Vaccination on Meningococcal Carriage in Adolescents. Pediatr Infect Dis J. 2022 Nov 1;41(11):e468-e474. doi: 10.1097/INF.0000000000003660. Epub 2022 Jul 27.
- McMillan M, Koehler AP, Lawrence A, Sullivan TR, Bednarz J, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond PC, Marshall HS. B Part of It School Leaver Study: A Repeat Cross-Sectional Study to Assess the Impact of Increasing Coverage With Meningococcal B (4CMenB) Vaccine on Carriage of Neisseria meningitidis. J Infect Dis. 2022 Feb 15;225(4):637-649. doi: 10.1093/infdis/jiab444.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- HREC/16/WCHN/140_3
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Meningokokken
-
Shanghai Yuguan Biotech Co., Ltd.(Delonix Bioworks)RekrutierungNeisseria Meningitidis Serogruppe BAustralien
-
Public Health EnglandAbgeschlossenNeisseria Meningitidis Serogruppe BVereinigtes Königreich
-
Novartis VaccinesAbgeschlossenN. Meningitidis BeförderungVereinigtes Königreich
-
Sheffield Teaching Hospitals NHS Foundation TrustAbgeschlossenNeisseria lactamicaVereinigtes Königreich
-
GlaxoSmithKlineAbgeschlossenMeningokokken | Haemophilus influenzae Typ b | Neisseria Meningitidis-Haemophilus Influenzae Typ b-ImpfstoffPolen, Vereinigtes Königreich
-
PfizerAbgeschlossenNeisseria Meningitidis (bakterielle Meningitis) | Invasive Pneumokokken-Erkrankung (IPD)Deutschland
-
PfizerAbgeschlossenMeningitis | Meningokokken-Impfstoff | rLP2086 | Wiederholung | N Meningitidis Serogruppe BDeutschland, Finnland, Polen
-
GlaxoSmithKlineAbgeschlossenHepatitis B | Keuchhusten | Tetanus | Diphtherie | Hib-Erkrankungen | Neisseria Meningitidis Serogruppen A und C KrankheitenPhilippinen
-
University of AdelaideAbgeschlossenMeningokokken-Infektionen | Neisseria-Infektion | Neisseria-Meningitis-SepsisAustralien
-
Foundation for Professional Development (Pty) LtdFoundation for Innovative New Diagnostics, SwitzerlandRekrutierung